Ann: Notices received under s203D and s249D of Corporations Act, page-57

Apologies, looking back at my emails, I had initially queried whether the topline data package had included any non-functional data on 19 Dec.

This *did* get a response:

We do expect to receive additional data in January, and this will include all lab results. As you note, we will be working through this as it comes in and will look forward to sharing any findings with investors in due course.

It was my follow up on 20 Dec, where I tried to confirm that the above meant that they hadn't seen any lab results at all that went unanswered.

TBH by this arvo I'd forgotten that they'd even mentioned available secondary endpoints. Would be nice to know which of Grip/Pinch, Respiratory Function & Quality of Life they've seen...

Cancelling a trial that isn't meeting the primary or "available" (lol) secondary endpoints makes sense to me, even if those endpoints are purely functional. You aren't getting approved without displaying benefit**?

I still haven't seen anything indicating that they've seen lab data but can understand why you believe they have. Obviously I have a nagging doubt here, otherwise I wouldn't be asking the question of them a third time...

** May not apply to Sarepta.